Defending ‘Co‐offending’ Women: Recognising Domestic Abuse and Coercive Control in ‘Joint Enterprise' Cases Involving Women and their Intimate Partners

Abstract: The role of coercive control in women's offending has been increasingly recognised in law. Yet, there remains a significant blind spot that leads to grossly unfair outcomes for women who are implicated in cases of serious violence with their abusive partners. This article outlines the role that abusive relationships play in women being ‘associated’ with an offence, being present at the scene and unable to withdraw and being implicated in the police investigation. It argues that such relationships must be recognised in legal practice and in the law, to avoid serious miscarriages of justice being enacted upon women who have already been repeatedly failed by the State

Suppression, denial, sublimation: Defending against the initial pains of very long life sentences

The central purpose of the article is to explore the psychic components of the early pains of imprisonment described by male and female prisoners serving very long mandatory life sentences for murder. While there is a strong tradition of documenting prisoners’ adaptations to ‘life inside’, little work in prisons sociology explores how life-sentenced prisoners, specifically those convicted of murder, reactively respond and adjust to the early years of these sentences. Having outlined prisoners’ descriptions of entry shock, temporal vertigo and intrusive recollections, we draw upon a Freudian terminology of ‘defence mechanisms of the ego’ to argue that suppression, denial and sublimation represent key ways of ‘defending against’ (rather than ‘adapting to’) these experiences. We suggest that the particular offence–time nexus of our sample—the specific offence of murder combined with a very long sentence—helps to explain these defensive patterns.We are grateful for the support of by the Economic and Social Research Council [grant: ES/J007935/1], and the Isaac Newton Trust

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Joint enterprise in England and Wales: Why problems persist despite legal change

The law in England and Wales (as in Australia and other jurisdictions) enables a person to be convicted of an offence committed by another using complicity liability, sometimes termed ‘joint enterprise’. In England and Wales, joint enterprise has been widely criticised for: failing to distinguish between the moral and legal culpability of the person who commits the substantive offence and those on the periphery of it; being used disproportionality in cases involving young men from black and mixed ethnic backgrounds; and for lacking legal legitimacy. Thus, it was hoped that the abolition of the extended form of complicity liability in England and Wales – known as Parasitic Accessorial Liability (PAL) – by the Supreme Court in 2016, would rectify these issues. Reporting on interviews with police detectives, and prosecution and defence lawyers in England involved in cases of serious youth violence, this paper argues that the problems associated with 'joint enterprise’ in England and Wales remain, despite the change in the law. This is due to the only ‘subtle shift’ in practice and a continued reliance on racialised inferences about young men from black and mixed ethnic backgrounds. We suggest changes in practice are required, alongside meaningful law reform